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B) were included (14 hospitals). There were no signiﬁcant dif-
ferences concerning demographic data, clinical data and severity
of CAP classiﬁed according to PSI-score between the groups.
Total direct costs of CAP amounted to €1528.47 in A and
€1750.01 in B (p < 0.001). Costs for drug acquisition decreased
from €201.00 (A) to €136.55 (B). Costs for nursing and diag-
nostics were almost constant (nursing: A: €554.20, B: €539.25;
diagnostics: A: €79.72, B: €81.17). Hotel costs and costs for non-
medical therapy amounted to €640.03 (A) and €909.36 (B), 
(p < 0.001) and to €53.53 (A) and €83.41 (B), (p < 0.001),
respectively. CONCLUSIONS: Most important cost-driving
factors before and after DRG implementation were hotel and
nursing costs. Drug costs represent only a small part of total
costs and decreased during study period. The signiﬁcant increase
of hotel costs and costs for non-medical therapy may be caused
by higher energy and staff costs. No cost-saving was achieved
from hospital’s perspective after the implementation of DRG.
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OBJECTIVE: To determine the co-morbidity and economical
impact of treatment with tiotropium bromide (TB) for COPD,
in a population cared for by Spanish primary care teams (PCTs)
and specialized physicians, in the context of routine clinical prac-
tice. METHODS: A retrospective observational study including
patients receiving regular treatment with TB, and seen by four
PCTs and two hospital centers during 2004. Principal measures:
age-sex, episodes / co-morbidity, clinical parameters, resources
utilization and pharmacological groups. The costs model was
established differentiating semiﬁxed-indirect costs from the vari-
able costs (pharmacy, tests, referrals) in the PCTs, as well as the
visits, emergencies and hospital admissions registered in the ref-
erence hospital centers. A logistic regression analysis was made
for correlation of the model. The costs were contrasted by analy-
sis of covariance (ANCOVA), with the estimation of marginal
means (Bonferroni adjustment). RESULTS: Of 900 subjects with
COPD, 14.3% (n = 129) received treatment with TB (CI:
12.0–16.6%). The mean episodes/patient/year was 2.1 ± 1.4 vs.
1.8 ± 1.3 (p = NS), seriousness/severity 41.3% vs. 26.3% (p =
0.001), deﬁned daily dose (DDD) 5928.5 ± 9624.1 vs. 6187.7 ±
12471.3 (p = NS) and number visits/patient/year 15.1 ± 9.4 vs.
17.3 ± 11.9 (p = 0.044). After adjustment by age and sex, TB
use was associated with diabetes mellitus (OR = 1.6; CI =
1.0–2.5; p = 0.034) and patient severity (OR = 1.8; CI = 1.2–2.8;
p = 0.004). Quantiﬁcation of unit cost/year was €2793.22 ±
€3166.30 (€3354.17 ± €3423.25 vs. €2699.36 ± €3113.75; p =
0.001). The adjusted patient cost/year was €2831.22 (SE =
217.32) with TB versus €2786.86 € (SE = 88.53) without TB, 
p = NS. CONCLUSIONS: TB is associated as therapy comple-
menting habitual treatment, with the presence of diabetes, and
with the severity of the disease. The costs of COPD entail impor-
tant resource utilization. The prescription of TB does not imply
a greater global cost of the disease and could give rise to fewer
outpatient follow-up visits. Further studies are needed to conﬁrm
the consistency of the results obtained.
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OBJECTIVE: To compare the risk of hospitalizations and/or
emergency department (ED) visits among Medicaid COPD
patients prescribed various medications. This study analyzed
both COPD-related events and all-cause events. METHODS:
Observational, retrospective study in Texas Medicaid. Eligible
patients were aged 40 to 65 years, with a primary or secondary
diagnosis of COPD, and with > = 1 prescription for ipratropium
(IPR), inhaled corticosteroids (ICS), salmeterol (SAL) or ﬂutica-
sone proprionate/ salmeterol (FSC) between September 1, 2000,
and December 31, 2003. Outcome of interest was time to ﬁrst
ED/hospitalizations 12 months post index medication date. A
matched propensity sample was used as a sensitivity analysis.
RESULTS: A total of 9671 patients were included: IPR (5786),
ICS (1561), SAL (600), and FSC (1724). After adjusting for base-
line characteristics (prior ED/hospitalizations, oral corticos-
teroid, albuterol, theophylline use, comorbidities, asthma
diagnosis, age, race, and gender), compared with IPR, all cohorts
were associated with signiﬁcantly lower risk of a COPD-related
ED/hosp event; ICS (HR 0.822 95% CI, 0.694–0.974), SAL
(HR, 0.721 95% CI, 0.551–0.944), FSC (HR, 0.720 95% CI,
0.605–0.857). When comparing all-cause events, only FSC had
a signiﬁcantly lower risk than IPR (FSC, [HR 0.894 95% CI,
0.842–0.949]). Propensity matched sample of FSC versus IPR (1
: 1), showed that FSC had a lower risk for both COPD-related
(HR, 0.760 [95% CI, 0.617–0.936]) and all-cause (HR, 0.909
[95% CI, 0.845–0.978]) ED/hosp events. CONCLUSIONS: FSC
was associated with a signiﬁcantly lower risk of COPD-related
and all-cause ED/hosp events compared with IPR during 12
months of therapy in a Medicaid population. Additional studies
are needed to conﬁrm these ﬁnding across different populations.
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OBJECTIVES: To quantify the economic consequences of the
lack of adherence to GOLD guidelines regarding treatment of
COPD in Spain. METHODS: A literature review was used to
identify observational studies describing drugs used in patients
with COPD and different levels of severity in Spain (FEV1 80%-
50% of predicted–mild- and FEV1 <50%–moderate/severe-). A
pooled analysis of these studies was combined with drug costs
(using different assumptions) to obtain the “observed cost” of
COPD treatment. An “expected cost” was obtained by using the
minimum and maximum treatment derived from GOLD recom-
mendations, so obtaining a range of the expected cost of med-
ications for COPD for different levels of severity. An economic
model was built up to compare different scenarios of “observed
vs expected” costs of COPD treatment and a Monte-Carlo sim-
ulation was carried out to estimate the proportion of patients in
the real word setting presenting higher or lower costs than the
range of ideal costs derived from GOLD recommendations.
RESULTS: Average medication cost of COPD patients in Spain
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was estimated from €1218 to €1314 per patient/year depending
on different assumptions. These ﬁgures were higher than the
ideal expected average cost derived from guidelines (from €1007
to €1021 per patient/year), so yielding to a potential reduction
of €198 to €293 per patient/year. Monte-Carlo simulation
showed that about 13% of patients in the real word setting pre-
sented higher treatment costs than the maximum expected cost.
This proportion was much higher in moderate/severe patients
compared to mild patients (28.0% and 11.1% respectively).
CONCLUSIONS: An improvement of the adherence to GOLD
guidelines in Spain should have not only clinical implications for
COPD patients, but also an economic beneﬁt for the National
Health System. The potential savings in terms of medications
costs have been estimated around 20% of the observed costs.
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OBJECTIVES: To evaluate the prevalence of pulmonary hyper-
tension (PH) in Germany as epidemiological data for PH are
lacking. METHODS: The study followed a top-down approach,
based on German secondary statistics (based on ICD-10 codes)
and published literature. Several secondary statistics were taken
into account: Ofﬁcial German statistics on nationwide mortality
rates, ADT (“AbrechnungsDatenTransfer”) panel data from
“Zentralinstitut für die kassenärztliche Versorgung”, and diag-
nosis statistics from IMS Health. Data on prevalence of PH
related to connective tissue diseases, HIV infection, chronic
obstructive pulmonary disease (COPD), obstructive sleep apnoea
syndrome (OSAS), left ventricular systolic dysfunction (LVSD)
and pulmonary embolism (PE) were extracted from published lit-
erature 1990 to 2006 (peer-reviewed journals). Numbers of PH
cases were extrapolated for Germany, based on prevalence data
for the underlying diseases. RESULTS: Based on secondary sta-
tistics, number of cases in 2002 with idiopathic pulmonary arte-
rial hypertension (ICD I27.0) ranged from 1400 to almost 2900
cases, and number of cases with unspeciﬁc pulmonary heart
disease (ICD 27.9) ranges from 1700 up to 10,400 cases. Based
on literature data, prevalence of PH in patients with diseases like
connective tissue diseases or HIV infection ranges between 2480
and 11,160 cases. PH caused by LVSD affects about 380,000
patients. Cases of PH associated with COPD, OSAS or PE range
from 191,160 to 496,320. Summing up, between 574,100 and
889,900 patients were estimated to be affected by PH. CON-
CLUSION: The presented analysis is the ﬁrst robust estimation
of the prevalence of PH for Germany. Although the subgroup of
pulmonary arterial hypertension (WHO Group I) is shown to be
rare, secondary forms with estimated 570,000 to 900,000
patients affected by PH should be considered of relevance in
regard to socioeconomic aspects. With respect to these numbers
the medical community should focus on structural aspects of care
for patients with this severe disease.
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OBJECTIVES: To analyse the utilisation of drugs for treatment
of respiratory diseases (ATC group: R) within Slovakia between
1996 and 2004 and to asses the economic consequences of 
the medications. METHODS: For 1996–2004, the data about 
consumption of drugs for treatment of respiratory diseases were
collected, in accordance with classiﬁcation ATC and DDD mea-
surement unit. This analysis focused on the situation in asthma
medication in more detail. Data of wholesalers, who are legally
obliged provide this information to the Slovak Institute for Drug
Control, was used for the analysis. The results were expressed
in the numbers of packages, ﬁnance units (€) and deﬁned daily
doses per 1000 inhabitants per day (DID). RESULTS: A signiﬁ-
cant increase in the medication of respiratory diseases (in 1996
(98.29), in 2000 (92.55) and in 2004 (134.11) in term of DID
can be seen from this analysis. The results show the consump-
tion (in term of DID) of selective beta-2-adrenoreceptor agonists
in 1996 (3.61), in 2000 (3.80) and in 2004 (2.55), adrenergics
in 1996 (1.40), in 2000 (2.04) and in 2004 (5.91), glucocorti-
coids in 1996 (1.43), in 2000 (4.18) and in 2004 (5.26), anti-
cholinergics in 1996 (0.38), in 2000 (1.37) and in 2004 (2.70),
xanthines in 1996 (7.24), in 2000 (8.80) and in 2004 (7.20),
leukotriene receptor antagonists in 1997 (0.03), in 2000 (0.33)
and in 2004 (0.44). In ﬁnancial terms, the consumption of 
selective beta-2-adrenoreceptor agonists (€2,385,000), adrener-
gics (€9,679,000), glucocorticoids (€3,810,000), anticholinergics
(€1,464,000), xanthines (€1,366,000), leukotriene receptor
antagonists (€1,649,000) for the year 2004 can be seen from this
study. CONCLUSIONS: Usage of generic drugs for the treatment
of respiratory diseases brought about a dramatic increase in the
consumption of drugs in this ﬁeld but the ﬁnancial expenditures
for health insurance funds have been remained under control.
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OBJECTIVES: Expected Value of Perfect Information (EVPI)
analysis is a natural extension of probabilistic modelling and
provides information about the value of collecting additional
information to eliminate or reduce uncertainty. A partial EVPI
analysis provides information about the model parameters for
which the collection of additional data is most useful. The objec-
tive of this study is to determine the impact of additional data
collection on the remaining uncertainty in a probabilistic model
for the bronchodilator treatment of patients with chronic
obstructive pulmonary disease (COPD). The value of additional
information is weighted against the costs of collecting the data.
METHODS: We used a probabilistic Markov model with a time-
horizon of 5 years. Primary outcome parameters were the costs
per QALY. Stochastic input parameters of the model included
probabilities to transition between disease states, probabilities to
experience an exacerbation, and utilities and resource use asso-
ciated with disease states and exacerbations. Because utilities
proved to contribute substantially to the overall EVPI, additional
data about utilities associated with COPD severity states were
collected in 1235 patients participating in a randomised clinical
trial. RESULTS: Before collecting additional data the overall
